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Abstract
Background: Vision loss due to vascular disease of the retina is a leading cause of blindness in the world. Retinal
angiomatous proliferation (RAP) is a subgroup of neovascular age-related macular degeneration (AMD), whereby abnormal
blood vessels develop in the retina leading to debilitating vision loss and eventual blindness. The novel mouse strain,
neoretinal vascularization 2 (NRV2), shows spontaneous fundus changes associated with abnormal neovascularization. The
purpose of this study is to characterize the induction of pathologic angiogenesis in this mouse model.
Methods: The NRV2 mice were examined from postnatal day 12 (p12) to 3 months. The phenotypic changes within the
retina were evaluated by fundus photography, fluorescein angiography, optical coherence tomography, and
immunohistochemical and electron microscopic analysis. The pathological neovascularization was imaged by confocal
microscopy and reconstructed using three-dimensional image analysis software.
Results: We found that NRV2 mice develop multifocal retinal depigmentation in the posterior fundus. Depigmented lesions
developed vascular leakage observed by fluorescein angiography. The spontaneous angiogenesis arose from the retinal
vascular plexus at postnatal day (p)15 and extended toward retinal pigment epithelium (RPE). By three months of age,
histological analysis revealed encapsulation of the neovascular lesion by the RPE in the photoreceptor cell layer and
subretinal space.
Conclusions: The NRV2 mouse strain develops early neovascular lesions within the retina, which grow downward towards
the RPE beginning at p15. This retinal neovascularization model mimics early stages of human retinal angiomatous
proliferation (RAP) and will likely be a useful in elucidating targeted therapeutics for patients with ocular neovascular
disease.
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Introduction
Vision loss due to vascular disease of the retina is a leading cause
of blindness in the world and affects all age groups. Neovascular-
ization is a hallmark of complex, polygenic diseases, such as
retinopathy of prematurity, proliferative diabetic retinopathy, and
age-related macular degeneration (AMD). AMD, affects 1 in 3
individuals over age 65, occurs in two forms: exudative (‘‘wet’’)
and nonexudative (‘‘dry’’). Advanced exudative AMD is defined
by the formation of abnormal blood vessels that grow from the
choroidal vasculature, through breaks in Bruch’s membrane, into
the outer retina [1]. Less commonly, the abnormal vessels
originate from retinal vasculature and can form a retinal–
choroidal anastomosis (RCA) with the choroidal vascular bed
[1–4]. These blood vessels are immature and leaky, resulting in
subretinal and intraretinal edema and hemorrhage, which leads to
vision loss [1,5]. Neovascular AMD accounts for 10–15% of AMD
cases, and if left untreated, rapidly leads to substantial vision loss
[1,6]. In recent years, a subgroup of neovascular AMD coined as
retinal angiomatous proliferation (RAP) has been described where
PLOS ONE | www.plosone.org 1 September 2014 | Volume 9 | Issue 9 | e106507the disease starts as neovessels originating from the retinal vascular
bed and grow towards the outer retina, ultimately forming
choroidal neovascularization [7–9]. RAP [9], has been classified
into three stages: stage I, when intraretinal neovascularization
(IRN) arises from the deep capillary vascular plexus within the
retina; stage II, is determined by growth of these abnormal retinal
vessels into the subretinal space to form subretinal neovascular-
ization (SRN); and Stage III occurs when choroidal neovascular-
ization is observed, retinal–choroidal anastomosis (RCA) is a
persistent feature of this stage. While it is well known that RAP
follows a different natural course and response to treatment from
typical neovascular AMD [10], there are few established models
that allow us to fully understand the disease pathophysiology or to
test new treatments for RAP [11,12].
There are several animal models of retinal neovascularization
[13–17], however, the precise molecular mechanism of RAP
remains to be elucidated. The neoretinal vascularization (NRV) 2
mouse line, also called JR5558 mice, was discovered through The
Jackson Laboratory Eye Mutant Screening program, which has
identified a large number of new mouse models that exhibit
unique eye phenotypes [18]. In this study, we characterize a novel
mutant mouse model, NRV2, which appear to have a recessive
mode of inheritance characterized by multiple areas of retinal
depigmentation and vascular leakage in the posterior fundus. In
this study, we focused on the characterization of the early ocular
phenotype and etiology of angiogenesis in NRV2 mice. We
discovered that depigmentation and neovascularization occur
spontaneously and are concurrent with the presence of the
abnormal blood vessels in the photoreceptor cell layer of the
retina. Furthermore, NRV2 neovascularization originates from
the retinal vascular plexus and grows outwards to the subretinal
space, forming neovascularization structures at the RPE Bruch’s
membrane interface and mimicking the early clinical presentation
of RAP in humans. This genetic model of retinal neovasculariza-
tion will provide a significant tool that will aid in our
understanding of the molecular causes of retinal neovascular
disease as well as in developing preclinical therapeutics.
Materials and Methods
Animals
JR5558 mice were obtained from The Jackson Laboratory (Bar
Harbor, ME) and named neoretinal vascularization 2 (NRV2)
mice. As far as we have observed, there is close to 100%
penetrance of the ocular phenotype in this strain and we have not
found any other gross abnormalities in other organ systems to
date. All animal procedures adhered to the Association for
Research in Vision and Ophthalmology Statement for the Use of
Animals in Ophthalmic and Vision Research. The Animal Care
and Use Committee of Massachusetts Eye and Ear Infirmary
approved the protocol for experiments outlined herein. The n’s
expressed are reflective of an individual mouse, not an individual
eye.
Fundus photography
Fundus images were taken using the Micron III Retinal Imaging
Microscope (Phoenix Research Laboratories, Pleasanton, CA).
Mice were anesthetized with Avertin (Sigma, St. Louis, MO) and
placed on the 37uC heating pad to keep body temperature. The
pupils were dilated with 5% phenylephrine and 0.5% tropicamide.
Images were taken by attaching cornea covered with 2.5%
Goniovisc (HUB Pharmaceuticals, Rancho Cucamonga, CA) to
the Micron camera lens using the StreamPix software (Phoenix
Research Laboratories, Pleasanton, CA).
Fluorescein angiography
Fluorescein angiography (FA) was performed using a Micron III
Retinal Imaging system directly following imaging of the fundus.
Fluorescein images were captured at 3–5 minutes after i.p.
injection of 0.1 ml of 2% fluorescein sodium (Akorn, Lake Forest,
IL) and used to quantify the number of the vascular leakage areas.
The images were captured at 1, 3–5 and 10 minutes after injection
to define the time course of vascular leakage over time.
Spectral Domain Optical Coherence Tomography (SD-
OCT)
OCT images were taken using the Micron III Retinal Imaging
Microscope. OCT images were taken by line scan under the guide
of bright or Fluorescein field. The line scan is made up of a series
of 1024 single point A-scans.
Histology
Eyes were enucleated and fixed with Methanol/Acetic acid (3:1)
overnight at 4uC. Tissues were paraffin embedded. Serial 5 mm
thick sections were cut and stained with hematoxylin and eosin
(H&E), examined under bright field light microscopy.
Immunohistochemical Staining and 3D reconstruction of
retinal vascular structure
Eyes were enucleated and fixed in 4% paraformaldehyde for 1
hour at room temperature. Retinas were isolated and blocked in
PBS with 0.5% Triton X-100 and 5% goat serum. Retinas were
rinsed in PBS, permeabilized overnight at 4uC with 0.5% Triton
X-100 in PBS, and stained overnight with FITC-conjugated G.
simplicifolia isolectin B4 (Alexa Fluor 488-I21411, 1:100 dilution;
Life Technologies, Carlsbad, CA) in 1 mM CaCl2 in PBS. After 2
hours of washes, retinas were whole-mounted onto microscope
slides (Superfrost/Plus; Fisher Scientific, Pittsburgh, PA) with the
photoreceptor side down and embedded in reagent (PermaFluor;
Thermo Scientific, Fremont, CA). Retinal wholemounts were
visualized with a confocal microscope (SP5; Leica, Wetzlar,
Germany). Retinal vascular structures were reconstructed with
Amira 5.2 software (Visualization Sciences Group, Burlington,
MA) from the pictures taken by the confocal microscope.
Electron microscopy
Eyes were enucleated and cleaned of all extraneous tissue then
rinsed with saline. Eyes were immediately placed into fixative
consisting of 2.5% gluteraldehyde and 2% formaldehyde in 0.1 M
cacodylate buffer with 0.08 M CaCl2 at 4uC. After a short 10 to
15 minute fixation, eyes were bisected at the limbus and the
anterior segment was separated from the posterior segment and
the parts to be examined were placed back in the fixative. Within
24 hours of enucleation, the tissues were washed in 0.1 M
cacodylate buffer and stored at 4uC. The tissues were post-fixed
for 1.5 hours in 2% aqueous OsO4. The tissues were dehydrated
in graded ethanols, transitioned in propylene oxide, infiltrated
with propylene oxide and epon mixtures (tEpon, Tousimis)
embedded in epon and cured for 24–48 hours at 60uC. One-
micron sections were cut on a Leica Ultracut UCT and stained
with 1% toluidine blue in 1% borate buffer. Areas selected from
the 1 micron thick sections were further sectioned at 70–90 nm,
stained with saturated Uranyl Acetate and Sato’s lead stain and
examined with a Philips CM-10 electron microscope.
ELISAs for VEGF and sFLT-1
The retina tissue was homogenized with a lysis buffer (Roche
Diagnostics) containing protease inhibitors (Roche Diagnostics),
Retinal Neovascular Mouse Model
PLOS ONE | www.plosone.org 2 September 2014 | Volume 9 | Issue 9 | e106507and the homogenates were centrifuged at 16,2006g for 10 min at
4uC. The amounts of VEGF and sFLT-1 protein were assayed
using ELISA systems (R&D Systems).
Statistical analysis
Data are presented as means 6 SEM and were analyzed with
Student t test for comparisons between two groups. P value of ,
0.05 was considered statistically significant.
Results
Depigmentation and vascular leakage observed in
retinas of NRV2 mice
A longitudinal study was conducted to determine the onset and
progression of clinical manifestations of neovascular disease in
NRV2 mice. Fundus exams were performed using a fundus
imaging microscope at postnatal day p17 through postnatal day
p35. Diffuse areas of depigmentation were observed in the retina
beginning at p17 (Fig. 1A, Fig. S1A, B). Depigmented areas begin
to become more focal in nature and increase in number at p21
(Fig. 1B). The lesions become well demarcated and larger in size at
p25 (Fig. 1C). After p25, these areas become more diffuse in
nature (Fig. 1D, E, Fig. S1E, F). Vascular leakage was detected by
fluorescein angiography (FA). No leakage is observed at p17
(Fig. 1F, Fig. S1C, D). The vascular leakage pattern follows the
appearance of retinal depigmentation becoming evident at p21
(Fig. 1G) and peaks at p25, corresponding with the height of focal
depigmentation in these animals (Fig. 1H). The areas of depig-
mentation correlated with the development of vascular leakage,
indicating a vascular component to this disease phenotype. As with
the focal depigmentation, fluorescein leakage gradually decreased
after p25 (Fig. 1I, J, Fig. S1G, H). Early, moderate and late phase
fluorescein angiograms were performed to determine the degree of
vascular leakage in NRV2 mice. At p25, early leakage was
observed that became both brighter and larger in size as time
progressed to the late phase of the angiogram, indicating active
neovascularization (Fig. 2A–C). At p31, minimal leakage was
observed from the onset of the angiogram, which persisted
through the late phase without any further increase in leakage
(Fig. 2D–F), indicating that vascular leakage develops fairly early
in these mice at p25 and begins to resolve by p31. Longitudinal
fundus analysis from p21 through 16 weeks revealed both the
number of depigmentation areas (Fig. 3A) and FA leakage areas
(Fig. 3B) peaked at p25. By day 31 the areas of depigmentation
became more diffuse and enlarged, but the vascular leakage
largely subsided (Fig. 3A, B).
Spectral domain optical coherence tomography reveals
dysmorphic outer and inner retinal layers
Spectral domain optical coherence tomography (SD-OCT)
allows for a detailed, noninvasive evaluation of the retinal
architecture in vivo, and has been found to accurately reflect
retinal morphological changes that occur during retinal disease
progression. We followed lesion development in the NRV2 mouse
by SD-OCT at p17, p21, and p25. Depigmentation areas first
appear at p17, however, no vascular leakage is evident on FA
(Fig. 4A, B). In the SD-OCT, a disruption is apparent in the outer
plexiform layer (OPL) and a highly reflective lesion is present in
the inner segment/outer segment (IS/OS) (Fig. 4C). As the lesion
develops from p21–p25, the depigmentation area becomes more
prominent (Fig. 4D, G) and is associated with increased vascular
leakage (Fig. 4E, H) The SD-OCT assessment reveals enlarge-
ment of the subretinal and inner segment/outer segment (IS/OS)
zone along with a highly reflective area and persistent irregularity
of the ONL and OPL (arrows, Fig. 4C, F, I).
Retinal neovascular development in the NRV2 mouse
originates in the inner retina and extends outwards to
the RPE
Fundus characterization of the NRV2 eye strongly indicates the
presence of neovascular structures within retina. Retinal histology
was performed on NRV2 ocular tissue to determine the origin of
the neovascularization. Normal retina (Fig. 5A, B and Fig. S2) was
compared to retinal areas with lesions in the NRV2 mouse.
Retinal cross-sections revealed the presence of lesions containing a
lumenal structure near photoreceptor outer segments (Fig. 5C, D).
The abnormal vascular structure appears to originate from the
deep layer of the retinal vascular plexus, at the outer edge of the
inner nuclear layer (INL). Neovessels descend into the outer
nuclear layer (ONL), which is typically an avascular area, and then
Figure 1. Time course representing the morphological changes
found in the fundus of NRV2 mice. Fundus photographs and
fluorescein angiography of NRV2 mice from p17 to p35. (A–E) Fundus
images show the emergence of depigmented regions at p17 that
increase in size and number through p35. (F–J) Fluorescein angiography
indicates vascular leakage corresponding to the areas of depigmenta-
tion, peaking at p25 and subsiding by p35. n=10, Representative
images are shown. p=postnatal day.
doi:10.1371/journal.pone.0106507.g001
Retinal Neovascular Mouse Model
PLOS ONE | www.plosone.org 3 September 2014 | Volume 9 | Issue 9 | e106507reach the RPE and spread, initially, above the RPE (Fig. 5E, F).
The RPE and choriocapillaris appear normal in these sections.
These findings are supported by our SD-OCT images, which show
abnormal structures originating from the OPL and extending into
the subretinal space (Fig. 4C, D). However, it still remained
unclear if these vessels originated from the retinal vasculature or if
they were of choroidal origin, which subsequently anastamosed to
the outer retinal plexus. We assessed the formation of the
subretinal neovascular lesions in retinal flatmounts stained with
isolectin to gain a more complete understanding of the origin of
these vessels. A confocal z-stack was taken through the retina and
the vasculature was reconstructed into three-dimensional models
using Amira software. We assessed eyes at p12, p15, p17, p21 and
p25 in order to capture the development of these lesions. At p12,
normal reticulated retinal vasculature was present in the INL and
no abnormal vessels were observed in the ONL (Fig. 6B). In
contrast, beginning at p15, neovessels begin to grow and extend
into the ONL from the INL (Fig. 6C, movie S1). These vessels
continued to extend downward until they reach the RPE, where
they balloon above the RPE from p17 through p25 (Fig. 6C–E,
movie S2, S3).
Transmission electron microscopy (TEM) of NRV2 reveals
lesion architecture and development
Morphological features at the RPE-Bruch’s interface were
assessed using electron microscopy to further delineate ultrastruc-
tural characteristics of NRV2 neovascular lesions. The outer
segments, RPE, Bruch’s membrane, and choriocapillaris are well
organized in C57BL/6 mice (Fig. 7A). In contrast, new vessels are
evident at the photoreceptor outer segment-RPE interface at p21
in NRV2 mice (Fig. 7B). Here the outer segments appear
disorganized (damaged and or missing) and are lacking their
typical morphologic structure (Fig. 7B). Two new vessels are
observed among the outer segments above the RPE and
choriocapillaris, which appear normal at p21 (Fig. 7B). Higher
magnification of the lesion identifies pericytes that are clearly
evident around the new vessels in these lesions (Fig. 7C). These
new vessel structures are also observed in 3 months old NRV2
mice. However, by 3 months of age, the RPE layer is disrupted
and proliferating RPE cells have enveloped the neovascular lesion
(Fig. 7D).
Interestingly, there are infoldings of the RPE at the surface of
the cell in contact with the new vessels (Fig. 7E). The new vessels
in turn show fenestrations along this contact area, mimicking the
usual RPE- choriocapillaris interaction (Fig. 7F). Some of these
new vessels are located directly over the Bruch’s membrane
without an intervening RPE layer (Fig. 7G). Bruch’s membrane
appeared intact and the choriocapillaris seemed normal at all time
points as seen by Fig. 1C, by light microscopy and TEM using step
sections.
It is well known that vascular endothelial growth factor (VEGF)
is a potent inducer of intraocular neovascularization [19]. Several
clinical studies have demonstrated that Anti-VEGF monotherapy
has a certain inhibitory effect to RAP progression [20–22]. On the
other hand, soluble FLT-1 (also known as soluble VEGF receptor-
1) is a natural inhibitor of VEGF, which is produced in the
photoreceptor layer [23]. It binds VEGF and regulates VEGF-
mediated angiogenesis [24–26]. Both suppression of sFLT-1 by
neutralizing antibodies and conditional knockdown of sFLT-1 in
photoreceptor cells increased VEGF levels and caused vessels to
enter the normally avascular photoreceptor layer [23]. We
assessed the levels of VEGF and sFLT-1 in the retina of NRV2
Figure 2. Vascular leakage in retinal lesions of NRV2 mice
during postnatal development. Fluorescein angiography images
taken of NRV2 mice at the early through late phases after fluorescein
injection for p25 and p31. (A–C) At p25 NRV2 mice have increased
vascular leakage through the late phase of fluorescein angiography,
compare B and C. (D–F) By p31, there is reduced vascular leakage
relative to p25, that does not increase from the middle to late phase of
fluorescein angiography, compare E and F. Early=1 minute after
fluorescein injection, middle=3–5 minutes after fluorescein injection,
late=10 minutes after fluorescein injection. n=10, Representative
images are shown. p=postnatal day.
doi:10.1371/journal.pone.0106507.g002
Figure 3. The peak time for depigmentation and vascular
leakage in NRV2 mice is at p25. Developmental time course of
depigmentation and vascular leakage assessed by funduscopy and
fluorescein angiography in NRV2 mice. (A) Quantitation of the number
of depigmented regions observed by fundus imaging. The peak
number of depigmented regions occurs at p25, followed by a relative
stabilization. (B) Quantitation of the number of fluorescein angiography
leakage, measured by the number of leakage regions, also peaks at p25.
Each plot on the graph is an average of 10 eyes, p=postnatal day.
doi:10.1371/journal.pone.0106507.g003
Retinal Neovascular Mouse Model
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significantly higher than those of C57BL/6 control mice (Fig.
S3A). However, there was no significant difference between the
sFLT-1 levels in the retina of NRV2 mice and those of C57BL/6
mice (Fig. S3B), suggesting that overexpression of VEGF in the
retina is involved in the cause of retinal angiogenesis in NRV2
mice.
Discussion
In the present study, we characterized a novel mouse model of
ocular neovascular disease, NRV2, by fundus, histological, and
ultrastructural analysis. As shown in Figure 1–3, NRV2 mice
spontaneously develop retinal depigmentation and vascular
leakage in the fundus during early postnatal days. The NRV2
phenotype is bilateral with no bias for gender observed.
Additionally, gross observation revealed no differences in other
organs. Histological analysis revealed abnormal vessel structures
present from the outer plexiform layer to the retinal pigment
epithelium (Fig. 5C–F). Moreover, three-dimensional reconstruc-
tion of the retinal vasculature at p15 clearly demonstrates that
these neovessels originate from the deep retinal vascular plexus in
the outer plexiform layer, which grow through the outer retina
towards the subretinal space between p17–p25 (Fig. 6). SD-OCT
examination captured balloon-like neovessel structures in the
photoreceptor cell layer (Fig. 4C, F, I). We could not identify any
vascular structures of choroidal origin and three-dimensional
reconstruction images of vasculature did not show vessels growing
up from the choroidal vascular bed into the retina’s ONL layer.
Our findings indicate that the retinal origin of angiogenesis in
NRV2 mice is consistent with stage 1 and stage 2 of human RAP
Figure 4. Vascular leakage corresponds to disturbances in the
outer plexiform and outer nuclear layers of the retina. Images
showing the representative time course of lesion development in a
NRV2 mouse. (A–C) Fundus image taken at p17, showing areas that
have slight depigmentation, at the 1 o’clock position of the image (A,
left panel). In the same area, vascular leakage can be seen by fluorescein
angiography (B, middle panel). Examination by SD-OCT at the region of
vascular leakage (red bar in B) reveals a disturbance in the ONL and OPL
of the retina (C, right panel). Arrowheads point to the retinal
disturbance. (D–F) Fundus image taken at p21, of the same mouse,
shows increased depigmentation at the 1 o’clock position of the image
(D, left panel). In the same area vascular leakage can be seen by
fluorescein angiography (E, middle panel). Examination by SD-OCT at
the region of vascular leakage (red bar in E) reveals a disturbance in the
ONL and OPL of the retina (F, right panel). Arrowheads point to the
retinal disturbance. (G–I) Fundus image of the same mouse taken at
p25, the height of leakage in NRV2 mice, shows depigmentation, at the
1 o’clock position of the image (G, left panel). In the same area, vascular
leakage is pronounced compared to the earlier time points as seen by
fluorescein angiography (H, middle panel). Examination by SD-OCT at
the region of vascular leakage (red bar in H) reveals a disturbance in the
ONL and OPL of the retina (I, right panel). Arrowheads point to the
retinal disturbance. p=postnatal day, GC: ganglion cells; INL: inner
nuclear layer; OPL: outer plexiform layer; ONL: outer nuclear layer; IS/OS:
photoreceptor inner segment/outer segments. n=10, Representative
images are shown. Scale bars: 50 mm.
doi:10.1371/journal.pone.0106507.g004
Figure 5. Neovessels extend from the INL to the RPE in NRV2
mice. Retinal cross-sections stained by H&E through a neovascular
lesion. (A) Cross-section from a C57Bl6 mouse showing the normal
architecture of the retinal layers. (B) Higher magnification of (A) focusing
on the normal architecture between the ONL and RPE interface. (C)
Cross section from an NRV2 mouse at p25, showing a disturbance in the
outer retina. (D) Higher magnification of (C) to show that the lesion is at
the interface of the ONL and RPE, in the outer segments of the
photoreceptors. (E) Retinal cross-section from another NRV2 mouse at
p25, capturing the track of a neovessel spanning from the INL to the
RPE. (F) Higher magnification of (E) showing the vessel extending
through the ONL. Arrowheads in (C) and (E) indicate the lesion areas
that are magnified in (D) and (F). GC: ganglion cells; IPL: inner plexiform
layer; INL: inner nuclear layer; OPL: outer plexiform layer; ONL: outer
nuclear layer; IS/OS: photoreceptor inner segment/outer segments.
n=3, Representative images are shown. Scale bars: 25 mm.
doi:10.1371/journal.pone.0106507.g005
Retinal Neovascular Mouse Model
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N et al. concluded that the neovessels in this mouse model
originate from choriocapillaris [27]. They identify vascular
structures in the subretinal space by immunohistochemical and
histological analysis. Our ultrastrucutural analysis revealed that
NRV2 neovessels proliferate into the subretinal space, located
between the RPE and photoreceptor cell layer (Fig. 7B). As the
neovascular lesions age, the neovessels become encapsulated by
RPE (Fig. 7D) and likely blocks the fluorescein leakage initially
seen from p21 to p25 (Fig. 1). Moreover, it was also observed that
the neovessels can descend to the border of Bruch’s membrane at
three months with no RPE cells or processes between the vessels
and Bruch’s membrane (Fig. 7G). However, no breaks in Bruch’s
membrane were ever identified in serial light or electron
microscopic sections and the choriocapillaris morphology was
normal. These findings further suggest that neovessels in NRV2
mice are of retinal origin and the growth of the neovessels into the
subretinal space corresponds to the stage 2 of human RAP. Mu ¨ller
cells play an important role for retinal homeostasis [28]. Recently,
it has been shown that ablation of Mu ¨ller cells results in
intraretinal neovascularization and vascular leakage [29]. How-
ever, in NRV2 mice, GFAP positive glial cells accumulated close
to the neovascular area in the retina [27]. They might have pro-
angiogenic effects in this mouse strain because Mu ¨ller cells are also
known to be a source of VEGF and TNF in hypoxic or
inflammatory conditions [30]. The role of Mu ¨ller cells in NRV2
mice remains to be elucidated.
Interestingly, the NRV2 neovessels were found to have
fenestrations similar to the choriocapillaris (Fig. 7E, F). Previous
reports show that RPE cells play an essential role in the
development and maintenance of fenestrated choroidal vascula-
ture [31]. RPE cells are also reported to have the ability to induce
fenestrations in endothelial cells of retinal vessels by encapsulating
them [32]. Given these prior findings, we propose that these
retinal neovessels originate from the deep retinal vascular plexus
and extend downward through the retina until they reach the RPE
where they proliferate until RPE cells encapsulate the lesions,
isolating them from the retinal microenvironment.
Yannuzzi et al. proposed three-stages of retinal angiomatous
proliferation in AMD [9]. They considered the origin of the
neovascularization in RAP to be derived from the inner retina. In
the early stage of RAP, angiomatous proliferation arises sponta-
neously from intraretinal capillaries. During the second stage, the
intraretinal neovessels extends outwards into the subretinal space.
Finally, choroidal neovascularization occurs and forms retinal-
choroidal anastomoses. In contrast, Gass et al. [33] suggested that
focal atrophy of the RPE and type 1 occult choroidal neovascu-
larization under the RPE are the initial lesions of RAP. These
lesions permit the retinal neovasculature to infiltrate into the outer
retina and form chorioretinal anastomoses with the original type 1
occult choroidal vessel. Using immunohistochemistry, Shimada et
al. demonstrated the existence of intraretinal neovascularization,
but not choroidal neovascularization, in excised RAP specimens
from patients with stage 2 RAP [34]. They also showed that both
choroidal neovascularization and chorioretinal anastomosis exist-
ed in the stage 3 RAP specimens. Their histopahological findings
supported Yannuzzi’s original hypothesis, in which RAP originates
from the inner retina [9].
Several mouse models have been reported to show RCA, which
is seen in stage 3 of RAP [35–37]. Very low-density lipoprotein
receptor (VLDLR) knock out mice begin to show abnormal retinal
blood vessels originating from the outer plexiform layer and grow
into the subretinal space around p14 [35], which is similar to the
process of NRV2 mice. In the VLDLR knock out mouse model,
RCA occurs approximately at 10 months of age and RPE cells
surround the vessels [36]. Additionally, photoreceptor degenera-
tion and the loss of the ONL were also observed [36]. In contrast,
the neovascularization in mice lacking CYP27A1, which is the
principal cholesterol hydroxylase in the retina, occurred in both
retina and choroid [37]. This angiogenesis process was detected
around 1.5 months. The major abnormalities included dilated
blood vessels in the OPL and thickened fibrovascular structures
between the RPE and Bruch’s membrane. The RCA formation
was observed at 11 months, which is later than VLDLR knock out
mice. This angiogenesis process might be more representative of
Gass’s original hypothesis [33]. Electron microscopy of NRV2
mice revealed significant RPE disturbances in the lesion of these
animals (Fig. 7D). The changes of RPE morphology would be
consistent with decreased oxygen supply to the outer retina due to
Figure 6. Neovessels originate from the INL and grow towards
the RPE in NRV2 mice. Retinal cross-sections stained with isolectin B4
that have been reconstructed into 3D images (Amira software) using
confocal Z stacks to show the development of retinal blood vessels in
NRV2 mice. (A) Low magnification overview of the 3D reconstruction of
a retinal flatmount stained with isolectin B4 for blood vessels. (B–F) High
magnification images of retinal cross-sections from NRV2 mice stained
with isolectin B4 that have been reconstructed into a 3D montage. (B)
At p12, there are only vessels in the INL with no apparent irregular
vessel development. (C) At p15, vessels are found extending from the
INL towards the RPE cell layer. (D) At p17, the vessels have reached the
RPE interface. (E) At p21, vessels have mostly interfaced with the RPE
cell layer and have begun to expand across the surface of the RPE. (F)A t
p25, the vessels have fully interacted with the RPE and formed balloon
like structures. p=postnatal day, INL: inner nuclear layer; OPL: outer
plexiform layer; ONL: outer nuclear layer; IS/OS: photoreceptor inner
segment/outer segments. The upper black square shows the border of
the OPL and ONL. The lower black square shows the interface of the
RPE layer. n=3/timepoint, Representative images are shown. Scale bars:
(A): 500 mm, (B–F): 50 mm.
doi:10.1371/journal.pone.0106507.g006
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to a rise in the ischemic factors, inflammatory factors, and retinal
angiogenesis in this mouse strain. However, we did not observe any
features of choroidal involvement, as seen in RCA, at any of the time
points examined in NRV2 mice. Further observation is needed to
elucidate the progression of RCA in this mouse model.
In conclusion, the origin and progression of angiogenesis
observed in the NRV2 mouse strain closely resembles human
RAP. The underlying etiopathogenesis, including genetic etiology
and mode of disease progression in patients with RAP, is not well
defined, in spite of several mouse models of RCA. Therefore,
future studies using the NRV2 mouse could include genetic
analysis that defines the specific genes and pathways involved in
the angiogenic process, along with the role of potential growth
factors that guide the neovessels to extend from the inner retina
towards the choroid. This study begins to define a novel mouse
model of ocular neovascularization that could become an
important tool in developing future anti-angiogenic therapies.
Supporting Information
Figure S1 The fundus morphological changes found in
NRV2 mice. Fundus photographs and fluorescein angiography
of NRV2 mice at p17 (A–D),2M( E, G) and 3 M (F, H).( A, B)
Fundus images showed the emergence of depigmented regions at
p17. (C, D) Fluorescein angiography did not show any vascular
leakage corresponding to the areas of depigmentation at p17. (E,
F) The depigmentation areas become faint at 2 M (E) and faded
away at 3 M (F). (G, H) Fluorescein leakage almost disappeared
after 2 M. Fluorescein angiography images were taken 3 minutes
after fluorescein intraperitoneal injection; n=5–10, Representa-
tive images are shown. p=postnatal day.
(TIF)
Figure S2 H&E section of normal C57BL/6 mouse
retina. Retinal cross-sections of normal C57BL/6 mouse at
p30 stained by H&E. (A) Cross-section from a C57BL/6 mouse
showing the normal architecture of the retinal layers. (B) Higher
magnification of (A) focusing on the normal architecture between
the ONL and RPE interface. n=3. Scale bars: 25 mm.
(TIF)
Figure S3 VEGF and sFLT-1 protein expression in the
retina of NRV2 mice. (A) VEGF and (B) sFLT-1 protein
concentration in the retina of NRV2 mice were quantified by
ELISA and compared to age-matched C57BL/6 mice at several
time points. (A) VEGF expression in NRV2 mice was significantly
higher than C57BL/6 mice at p12, p17, p21, and p30. (B) sFLT-1
didn’t show any significant differences between NRV2 and
C57BL/6. n=3/timepoint *P,0.05, **P,0.01.
(TIF)
Movie S1 The rotation image of 3D retinal vascular
structure of NRV2 mouse at p15 from Figure 6C.
(MOV)
Movie S2 Confocal images were taken every 1 micron in
the p25 retinal flat mount stained with isolectin B4.
Images were compiled sequentially, from superficial layers to deep
layers, into video format. These images were used for making the
3D images of Fig. 6F and Movie S3.
(MOV)
Movie S3 The rotation image of 3D retinal vascular
structure of NRV2 mouse at p25 from Figure 6F.
(MOV)
Figure 7. Neovessels that interface with the RPE form characteristic morphological features of more mature vessels. Electron
micrographs taken of NRV2 mice illustrate commonly observed morphological findings of neovessels when they come in contact with the RPE/
Bruch’s membrane. (A) Electron micrograph of a C57BL/6 mouse at 3 months of age shows the normal architecture of the outer retina. (B) Neovessels
(outlined in black) from an NRV2 mouse at p21, surrounded by disorganized outer photoreceptor segments. (C) High magnification image (red box in
B) that shows the presence of pericytes in the neovessels. (D) A 3 months old, NRV2 mouse with an RPE cell (outlined in black) surrounding the
neovessel. (E) High magnification (red box in D) that shows a contact point between the neovessel and RPE cell. (F) Higher magnification (red box in
E) of the contact point reveals fenestrations (arrowheads). (G) A 3 months old, NRV2 mouse where the neovessel has come in direct contact with the
Bruch’s membrane. IS: inner segment; OS: outer segment; MV: microvilli; BM: Bruch’s membrane; CC: choriocapillaris; NV: new vessels; P: pericyte;
n=3/timepoint, Representative images are shown. Scale bars: (A–D, G): 5 mm, (E, F): 1 mm.
doi:10.1371/journal.pone.0106507.g007
Retinal Neovascular Mouse Model
PLOS ONE | www.plosone.org 7 September 2014 | Volume 9 | Issue 9 | e106507Acknowledgments
Research reported in this publication was supported by a Special Scholar
Award (to K.M.C.) and unrestricted grant (to J.W.M.) from Research to
Prevent Blindness as well as a Bright Focus Foundation grant (K.M.C. and
N.H.). Additionally, research reported in this publication was supported by
National Eye Institute of the National Institutes of Health under award
numbers: R01EY022084/S1 (K.M.C.) and P30EY014104. The content is
solely the responsibility of the authors and does not necessarily represent
the official views of the National Institutes of Health.
Author Contributions
Conceived and designed the experiments: EH DH NH KMC JM.
Performed the experiments: EH NAM AMO HS KS YH KMC. Analyzed
the data: EH AMO NAM KMC DH HS. Contributed reagents/
materials/analysis tools: BC AEB RJD DGV. Contributed to the writing
of the manuscript: EH HS DH NH KMC JM.
References
1. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY (2012) Age-related
macular degeneration. Lancet 379: 1728–1738.
2. Jager RD, Mieler WF, Miller JW (2008) Age-related macular degeneration.
N Engl J Med 358: 2606–2617.
3. Zhang K, Zhang L, Weinreb RN (2012) Ophthalmic drug discovery: novel
targets and mechanisms for retinal diseases and glaucoma. Nature reviews Drug
discovery 11: 541–559.
4. Liakopoulos S, Ongchin S, Bansal A, Msutta S, Walsh AC, et al. (2008)
Quantitative optical coherence tomography findings in various subtypes of
neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 49:
5048–5054.
5. Gragoudas ES, Adamis AP, Cunningham ET, Jr., Feinsod M, Guyer DR (2004)
Pegaptanib for neovascular age-related macular degeneration. The New
England journal of medicine 351: 2805–2816.
6. Miller JW (2013) Age-related macular degeneration revisited–piecing the puzzle:
the LXIX Edward Jackson memorial lecture. Am J Ophthalmol 155: 1–35 e13.
7. Hartnett ME, Weiter JJ, Garsd A, Jalkh AE (1992) Classification of retinal
pigment epithelial detachments associated with drusen. Graefes Arch Clin Exp
Ophthalmol 230: 11–19.
8. Hartnett ME, Weiter JJ, Staurenghi G, Elsner AE (1996) Deep retinal vascular
anomalous complexes in advanced age-related macular degeneration. Ophthal-
mology 103: 2042–2053.
9. Yannuzzi LA, Negrao S, Iida T, Carvalho C, Rodriguez-Coleman H, et al.
(2001) Retinal angiomatous proliferation in age-related macular degeneration.
Retina 21: 416–434.
10. Viola F, Massacesi A, Orzalesi N, Ratiglia R, Staurenghi G (2009) Retinal
angiomatous proliferation: natural history and progression of visual loss. Retina
29: 732–739.
11. Bottoni F, Massacesi A, Cigada M, Viola F, Musicco I, et al. (2005) Treatment of
retinal angiomatous proliferation in age-related macular degeneration: a series of
104 cases of retinal angiomatous proliferation. Arch Ophthalmol 123: 1644–
1650.
12. Silva RM, Cachulo ML, Figueira J, de Abreu JR, Cunha-Vaz JG (2007)
Chorioretinal anastomosis and photodynamic therapy: a two-year follow-up
study. Graefes Arch Clin Exp Ophthalmol 245: 1131–1139.
13. Okamoto N, Tobe T, Hackett SF, Ozaki H, Vinores MA, et al. (1997)
Transgenic mice with increased expression of vascular endothelial growth factor
in the retina: a new model of intraretinal and subretinal neovascularization.
Am J Pathol 151: 281–291.
14. Tobe T, Okamoto N, Vinores MA, Derevjanik NL, Vinores SA, et al. (1998)
Evolution of neovascularization in mice with overexpression of vascular
endothelial growth factor in photoreceptors. Invest Ophthalmol Vis Sci 39:
180–188.
15. Ohno-Matsui K, Hirose A, Yamamoto S, Saikia J, Okamoto N, et al. (2002)
Inducible expression of vascular endothelial growth factor in adult mice causes
severe proliferative retinopathy and retinal detachment. Am J Pathol 160: 711–
719.
16. Lai CM, Dunlop SA, May LA, Gorbatov M, Brankov M, et al. (2005)
Generation of transgenic mice with mild and severe retinal neovascularisation.
Br J Ophthalmol 89: 911–916.
17. Yetemian RM, Brown BM, Craft CM (2010) Neovascularization, enhanced
inflammatory response, and age-related cone dystrophy in the Nrl2/2
Grk12/2 mouse retina. Invest Ophthalmol Vis Sci 51: 6196–6206.
18. Won J, Shi LY, Hicks W, Wang J, Hurd R, et al. (2011) Mouse model resources
for vision research. J Ophthalmol 2011: 391384.
19. Miller JW, Le Couter J, Strauss EC, Ferrara N (2013) Vascular endothelial
growth factor a in intraocular vascular disease. Ophthalmology 120: 106–114.
20. Saito M, Iida T, Kano M (2013) Two-year results of combined intravitreal anti-
VEGF agents and photodynamic therapy for retinal angiomatous proliferation.
Jpn J Ophthalmol 57: 211–220.
21. Engelbert M, Zweifel SA, Freund KB (2009) ‘‘Treat and extend’’ dosing of
intravitreal antivascular endothelial growth factor therapy for type 3 neovascu-
larization/retinal angiomatous proliferation. Retina 29: 1424–1431.
22. Hemeida TS, Keane PA, Dustin L, Sadda SR, Fawzi AA (2010) Long-term
visual and anatomical outcomes following anti-VEGF monotherapy for retinal
angiomatous proliferation. Br J Ophthalmol 94: 701–705.
23. Luo L, Uehara H, Zhang X, Das SK, Olsen T, et al. (2013) Photoreceptor
avascular privilege is shielded by soluble VEGF receptor-1. Elife 2: e00324.
24. Kendall RL, Thomas KA (1993) Inhibition of vascular endothelial cell growth
factor activity by an endogenously encoded soluble receptor. Proc Natl Acad
Sci U S A 90: 10705–10709.
25. Lai CM, Shen WY, Brankov M, Lai YK, Barnett NL, et al. (2005) Long-term
evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in
mice and monkeys. Mol Ther 12: 659–668.
26. Lukason M, DuFresne E, Rubin H, Pechan P, Li Q, et al. (2011) Inhibition of
choroidal neovascularization in a nonhuman primate model by intravitreal
administration of an AAV2 vector expressing a novel anti-VEGF molecule. Mol
Ther 19: 260–265.
27. Nagai N, Lundh von Leithner P, Izumi-Nagai K, Hosking B, Chang B, et al.
(2014) Spontaneous CNV in a novel mutant mouse is associated with early
VEGF-A-driven angiogenesis and late-stage focal edema, neural cell loss, and
dysfunction. Invest Ophthalmol Vis Sci 55: 3709–3719.
28. Reichenbach A, Bringmann A (2013) New functions of Muller cells. Glia 61:
651–678.
29. Shen W, Fruttiger M, Zhu L, Chung SH, Barnett NL, et al. (2012) Conditional
Mullercell ablation causes independent neuronal and vascular pathologies in a
novel transgenic model. J Neurosci 32: 15715–15727.
30. Eichler W, Yafai Y, Wiedemann P, Reichenbach A (2004) Angiogenesis-related
factors derived from retinal glial (Muller) cells in hypoxia. Neuroreport 15:
1633–1637.
31. Marneros AG, Fan J, Yokoyama Y, Gerber HP, Ferrara N, et al. (2005)
Vascular endothelial growth factor expression in the retinal pigment epithelium
is essential for choriocapillaris development and visual function. Am J Pathol
167: 1451–1459.
32. Burns MS, Hartz MJ (1992) The retinal pigment epithelium induces fenestration
of endothelial cells in vivo. Curr Eye Res 11: 863–873.
33. Gass JD, Agarwal A, Lavina AM, Tawansy KA (2003) Focal inner retinal
hemorrhages in patients with drusen: an early sign of occult choroidal
neovascularization and chorioretinal anastomosis. Retina 23: 741–751.
34. Shimada H, Kawamura A, Mori R, Yuzawa M (2007) Clinicopathological
findings of retinal angiomatous proliferation. Graefes Arch Clin Exp
Ophthalmol 245: 295–300.
35. Heckenlively JR, Hawes NL, Friedlander M, Nusinowitz S, Hurd R, et al. (2003)
Mouse model of subretinal neovascularization with choroidal anastomosis.
Retina 23: 518–522.
36. Hu W, Jiang A, Liang J, Meng H, Chang B, et al. (2008) Expression of VLDLR
in the retina and evolution of subretinal neovascularization in the knockout
mouse model’s retinal angiomatous proliferation. Invest Ophthalmol Vis Sci 49:
407–415.
37. Omarova S, Charvet CD, Reem RE, Mast N, Zheng W, et al. (2012) Abnormal
vascularization in mouse retina with dysregulated retinal cholesterol homeosta-
sis. J Clin Invest 122: 3012–3023.
Retinal Neovascular Mouse Model
PLOS ONE | www.plosone.org 8 September 2014 | Volume 9 | Issue 9 | e106507